Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma

The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma

(2016) Kim Margolin   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities

(2016) Martin Lauss et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade

(2016) Michal Lotem et al.   Journal of Immunology Research

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy

(2015) Helena Cirenajwis et al.   Oncotarget

EMT, CTCs and CSCs in tumor relapse and drug-resistance

(2015) Abhisek Mitra et al.   Oncotarget

Alpha-Catulin Contributes to Drug-Resistance of Melanoma by Activating NF-κB and AP-1

(2015) Birgit Kreiseder et al.   PLoS One

Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma

(2015) Aparna Jayachandran et al.   Oncotarget

Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy

(2014) K. Kemper et al.   CANCER RESEARCH

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

Directed Phenotype Switching as an Effective Antimelanoma Strategy

(2013) Magalí Sáez-Ayala et al.   CANCER CELL

Cancer stem cells: The challenges ahead

(2013) Jan Paul Medema   NATURE CELL BIOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion

(2012) J Ferguson et al.   ONCOGENE

Systematic classification of melanoma cells by phenotype-specific gene expression mapping

(2012) Daniel S. Widmer et al.   Pigment Cell & Melanoma Research

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer

(2010) Magdalena Zajac et al.   BMC Medical Genomics

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

(2010) Alexander Roesch et al.   CELL

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

(2010) A Singh et al.   ONCOGENE

Cancer stem cells versus phenotype-switching in melanoma

(2010) Keith S. Hoek et al.   Pigment Cell & Melanoma Research

Molecular Characterization of c-Abl/c-Src Kinase Inhibitors Targeted against Murine Tumour Progenitor Cells that Express Stem Cell Markers

(2010) Thomas Kruewel et al.   PLoS One

A Gene Expression Signature of Invasive Potential in Metastatic Melanoma Cells

(2009) Aaron R. Jeffs et al.   PLoS One

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

(2008) K. S. Hoek et al.   CANCER RESEARCH

Regulation of melanin synthesis by the TGF-β family in B16 melanoma cells

(2008) Masaru Murakami et al.   MOLECULAR BIOLOGY REPORTS